New drugs offer hope for migraine prevention

Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

Both studies involve drugs that are aimed at preventing attacks from occurring, rather than stopping the attacks once they have started. These studies are the first to test monoclonal antibodies for the prevention of migraine, and both are directed against a relatively new target in migraine prevention, the calcitonin gene-related peptide, or CGRP. CGRP has been thought to be important in migraine, but never have drugs been developed to specifically target the protein.

Both are phase II studies, meaning larger studies are needed to confirm the results.

One study involved 163 people who had migraine from five to 14 days per month. They received either a placebo or a single IV dose of a called ALD403 and then were followed for 24 weeks. Those who received the drug had an average of 5.6 fewer migraine days per month, a 66-percent decrease, compared to 4.6 fewer days per month for those who received a placebo, or a 52-percent decrease. Sixteen percent of those who received the drug had no migraine days at 12 weeks, while none of those who received the placebo were free from migraine at that point.

There were no differences in side effects between those receiving the drug and those receiving the placebo.

"These results may potentially represent a new era in preventive therapy for migraine," said Peter Goadsby, MD, PhD, of the UC San Francisco and a member of the American Academy of Neurology, who is an author on both studies.

"Migraine remains poorly treated, and there are few effective and well tolerated treatments approved that prevent attacks from occurring," said David Dodick, MD, of Mayo Clinic Arizona in Phoenix and a member of the American Academy of Neurology, who was also an author on both studies. "There is a huge treatment need for migraine – the third most common and seventh most disabling medical disorder in the world."

In the other study, 217 people who had migraine four to 14 days per month received biweekly subcutaneous injections of either a placebo or a drug called LY2951742 for 12 weeks.

Those who received the drug had an average of 4.2 fewer migraine days per month at 12 weeks, or a 63-percent decrease, while those who received had 3 fewer migraine days per month, or a 42-percent decrease. Those who received the drug were more likely to have side effects including pain at the injection site, upper and abdominal pain, but overall the drug was considered to be safe and well-tolerated.

"We're cautiously optimistic that a new era of mechanism-based is beginning," Dodick said.

add to favorites email to friend print save as pdf

Related Stories

Can nerve stimulation help prevent migraine?

Feb 06, 2013

Wearing a nerve stimulator for 20 minutes a day may be a new option for migraine sufferers, according to new research published in the February 6, 2013, online issue of Neurology, the medical journal of the American Academ ...

Does more stress equal more headaches?

Feb 19, 2014

A new study provides evidence for what many people who experience headache have long suspected—having more stress in your life leads to more headaches. The study released today will be presented at the American Academy ...

Combination drug taken early relieves migraine symptoms

Jul 07, 2008

A combination drug taken within an hour after the start of a migraine is effective in relieving symptoms, according to research published in the July 8, 2008, issue of Neurology, the medical journal of the American Academ ...

Recommended for you

Steering the filaments of the developing brain

2 hours ago

During brain development, nerve fibers grow and extend to form brain circuits. This growth is guided by molecular cues (Fig. 1), but exactly how these cues guide axon extension has been unclear. Takuro Tojima ...

Do we really only use 10% of our brain?

3 hours ago

As the new film Lucy, starring Scarlett Johansson and Morgan Freeman is set to be released in the cinemas this week, I feel I should attempt to dispel the unfounded premise of the film – that we only use 10% of our brains ...

Birthday matters for wiring-up the brain's vision centers

Jul 31, 2014

Researchers at the University of California, San Diego School of Medicine have evidence suggesting that neurons in the developing brains of mice are guided by a simple but elegant birth order rule that allows them to find ...

User comments